Selexipag, an Oral Prostacyclin-Receptor Agonist for Pulmonary Arterial Hypertension.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

To evaluate the data supporting the approval of selexipag and discuss its potential place in therapy for managing pulmonary arterial hypertension (PAH).

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Ann Pharmacother

Title: The Annals of pharmacotherapy

Publisher: SAGE Publications

ISSN (Electronic): 1542-6270

ISSN (Print): 1060-0280

Publication date (Electronic): Jun 2017

Volume: 51

Issue: 6

Affiliations

[1 ] 1 University of Connecticut, Storrs, CT, USA.

[2 ] 2 Center for Advanced Heart Failure and Transplant, Hartford, CT, USA.

[3 ] 3 University of Connecticut/Hartford Hospital, CT, USA.

[4 ] 4 University of Connecticut School of Medicine, Hartford, CT, USA.

Article

DOI: 10.1177/1060028017697424

PubMed ID: 28478717

SO-VID: 94e5fdd6-3601-40d6-a624-c916e35efcb5

History

Keywords: prostacyclin-receptor agonist,pulmonary arterial hypertension,selexipag

Data availability:

Keywords: prostacyclin-receptor agonist, pulmonary arterial hypertension, selexipag

Selexipag, an Oral Prostacyclin-Receptor Agonist for Pulmonary Arterial Hypertension.

Read this article at

Abstract

Related collections

Measurement of Glucocorticoid Receptor Signaling in Major Depression

Author and article information

Journal

Affiliations

Article

History

Comments

Comment on this article

Cited by 2